APA (7th ed.) Citation

Hirji, I., Cocks, K., Moreno‐Koehler, A., & Sundberg, A. (2023). Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial. Transplant Infectious Disease, 25(3), 1. https://doi.org/10.1111/tid.14064

Chicago Style (17th ed.) Citation

Hirji, Ishan, Kim Cocks, Alejandro Moreno‐Koehler, and Aimee Sundberg. "Healthcare Resource Utilization of Maribavir Versus Investigator‐assigned Therapy in Transplant Recipients with Cytomegalovirus Infection Refractory (with or Without Genotypic Resistance) to Prior Treatment: Exploratory Analysis of the Phase 3 SOLSTICE Trial." Transplant Infectious Disease 25, no. 3 (2023): 1. https://doi.org/10.1111/tid.14064.

MLA (9th ed.) Citation

Hirji, Ishan, et al. "Healthcare Resource Utilization of Maribavir Versus Investigator‐assigned Therapy in Transplant Recipients with Cytomegalovirus Infection Refractory (with or Without Genotypic Resistance) to Prior Treatment: Exploratory Analysis of the Phase 3 SOLSTICE Trial." Transplant Infectious Disease, vol. 25, no. 3, 2023, p. 1, https://doi.org/10.1111/tid.14064.